Real Impact of Liver Cirrhosis on the Development of Hepatocellular Carcinoma in Various Liver Diseases-meta-analytic Assessment

Overview

Journal Cancer Med

Specialty Oncology

Date 2019 Feb 22

PMID 30791221

Citations 70

Authors

Kazuo Tarao

Akito Nozaki

Takaaki Ikeda

Akira Sato

Hirokazu Komatsu

Tatsuji Komatsu

Masataka Taguri

Katsuaki Tanaka

Affiliations

Soon will be listed here.

Abstract

Background: It is well known that the incidence of developing hepatocelluler carcinoma (HCC) is increased in liver cirrhosis of different etiologies. However, comparison of HCC incidence in various liver diseases has not yet been estimated. We surveyed this comparison.

Methods: The PubMed database was examined (1989-2017) for studies published in English language regarding the prospective follow-up results for the development of HCC in various liver diseases. A meta-analysis was performed for each liver disease.

Results: The annual incidence (%) of HCC in the non-cirrhotic stage and cirrhotic stage, and the ratio of HCC incidence in the cirrhotic stage/non-cirrhotic stage were as follows. (a) hepatitis B virus liver disease: 0.37%→3.23% (8.73-fold), (b) hepatitis C virus liver diseases: 0.68%→4.81% (7.07-fold), (c) primary biliary cholangitis (0.26%→1.79%, 6.88-fold), (d) autoimmune hepatitis (0.19%→0.53%, 2.79-fold), and (e) NASH (0.03%→1.35%, 45.00-fold). Regarding primary hemochromatosis and alcoholic liver diseases, only follow-up studies in the cirrhotic stage were presented, 1.20% and 2.06%, respectively.

Conclusions: When the liver diseases advance to cirrhosis, the incidence of HCC is markedly increased. The development of HCC must be closely monitored by ultrasonography, magnetic resonance imaging, and computed tomography, irrespective of the different kinds of liver diseases.

Citing Articles

Prevalence and prediction of hepatocellular carcinoma in alcohol-associated liver disease: a retrospective study of 136 571 patients with chronic liver diseases.

Chang B, Tian H, Huang A, Zhai X, Wang Q, Han L eGastroenterology. 2025; 2(1):e100036.

PMID: 39944749 PMC: 11731072. DOI: 10.1136/egastro-2023-100036.

Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?.

Smirne C, Crobu M, Landi I, Vercellino N, Apostolo D, Pinato D Viruses. 2025; 16(12.

PMID: 39772206 PMC: 11680226. DOI: 10.3390/v16121899.

Prognostic significance of the tumor budding and tumor-infiltrating lymphocytes in survival of hepatocellular carcinoma patients.

Shafiq A, Taha N, Zaky A, Mohammed A, Omran O, Abozaid L Int J Health Sci (Qassim). 2024; 18(6):10-19.

PMID: 39502429 PMC: 11533185.

Risk of Malignancy in Indeterminate Liver Nodules Among Patients with Cirrhosis: A Retrospective Cohort Study.

Yahia Y, Qasem M, Abbarh S, Saffo H, Obeidat I, Barjas H J Gastrointest Cancer. 2024; 56(1):1.

PMID: 39414724 PMC: 11485135. DOI: 10.1007/s12029-024-01122-7.

ASH1L in Hepatoma Cells and Hepatic Stellate Cells Promotes Fibrosis-Associated Hepatocellular Carcinoma by Modulating Tumor-Associated Macrophages.

Du Y, Wu S, Xi S, Xu W, Sun L, Yan J Adv Sci (Weinh). 2024; 11(45):e2404756.

PMID: 39377228 PMC: 11615825. DOI: 10.1002/advs.202404756.

References

Su T, Hu T, Chen C, Huang Y, Chuang W, Lin C . Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Liver Int. 2016; 36(12):1755-1764. DOI: 10.1111/liv.13253. View

El-Serag H, Tran T, Everhart J . Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004; 126(2):460-8. DOI: 10.1053/j.gastro.2003.10.065. View

Miyakawa H, Sato C, Tazawa J, Izumi N, Hattori K, Ebata A . A prospective study on hepatocellular carcinoma in liver cirrhosis: respective roles of alcohol and hepatitis C virus infection. Alcohol Alcohol Suppl. 1994; 29(1):75-9. View

Beasley R . Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer. 1988; 61(10):1942-56. DOI: 10.1002/1097-0142(19880515)61:10<1942::aid-cncr2820611003>3.0.co;2-j. View

Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm S, Christensen E . Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002; 97(11):2886-95. DOI: 10.1111/j.1572-0241.2002.07057.x. View

Benvegnu L, Chemello L, Noventa F, Fattovich G, Pontisso P, Alberti A . Retrospective analysis of the effect of interferon therapy on the clinical outcome of patients with viral cirrhosis. Cancer. 1998; 83(5):901-9. DOI: 10.1002/(sici)1097-0142(19980901)83:5<901::aid-cncr15>3.0.co;2-z. View

Wong G, Chan H, Mak C, Lee S, Ip Z, Lam A . Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013; 58(5):1537-47. DOI: 10.1002/hep.26301. View

Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch H, Strohmeyer G . Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985; 313(20):1256-62. DOI: 10.1056/NEJM198511143132004. View

Lin C, Lin C, Mo L, Chang C, Perng D, Hsu C . Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis. J Hepatol. 2012; 58(4):730-5. DOI: 10.1016/j.jhep.2012.11.045. View

10.

Chuang S, Lee Y, Wu G, Straif K, Hashibe M . Alcohol consumption and liver cancer risk: a meta-analysis. Cancer Causes Control. 2015; 26(9):1205-31. DOI: 10.1007/s10552-015-0615-3. View

11.

Bedogni G, Miglioli L, Masutti F, Ferri S, Castiglione A, Lenzi M . Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. Am J Gastroenterol. 2008; 103(9):2248-53. DOI: 10.1111/j.1572-0241.2008.01948.x. View

12.

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

13.

Gramenzi A, Andreone P, Fiorino S, Camma C, Giunta M, Magalotti D . Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut. 2001; 48(6):843-8. PMC: 1728334. DOI: 10.1136/gut.48.6.843. View

14.

Hui J, Kench J, Chitturi S, Sud A, Farrell G, Byth K . Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology. 2003; 38(2):420-7. DOI: 10.1053/jhep.2003.50320. View

15.

Montano-Loza A, Carpenter H, Czaja A . Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol. 2008; 103(8):1944-51. DOI: 10.1111/j.1572-0241.2008.01922.x. View

16.

Ioannou G, Splan M, Weiss N, McDonald G, Beretta L, Lee S . Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007; 5(8):938-45, 945.e1-4. DOI: 10.1016/j.cgh.2007.02.039. View

17.

Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G . Long-term survival in patients with hereditary hemochromatosis. Gastroenterology. 1996; 110(4):1107-19. DOI: 10.1053/gast.1996.v110.pm8613000. View

18.

Tarao K, Ohkawa S, Shimizu A, Harada M, Nakamura Y, Ito Y . Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus-positive cirrhotic patients. Cancer. 1994; 73(4):1149-54. DOI: 10.1002/1097-0142(19940215)73:4<1149::aid-cncr2820730405>3.0.co;2-9. View

19.

Teufel A, Weinmann A, Centner C, Piendl A, Lohse A, Galle P . Hepatocellular carcinoma in patients with autoimmune hepatitis. World J Gastroenterol. 2009; 15(5):578-82. PMC: 2653348. DOI: 10.3748/wjg.15.578. View

20.

Yeoman A, Al-Chalabi T, Karani J, Quaglia A, Devlin J, Mieli-Vergani G . Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening. Hepatology. 2008; 48(3):863-70. DOI: 10.1002/hep.22432. View